QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=0B3561E72662FBE6EB77424C6CF9E852;jsessionid=48FD400854722EAA9233B97BBB9A4283;jsessionid=60238739B2F34634A15F586986642293;jsessionid=9066F83F093952A2C700D8AE88761875;jsessionid=2EB981516E01CD98213D68F4C966FA78;jsessionid=F0D58779B34C6465231613701B112E50;jsessionid=D61B914D8FE7178E32486982387D2C57;jsessionid=19B23510BC05FA5090FF014E4C51F090 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
3. ATXN2 is a target of N-terminal proteolysis.
4. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
5. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=0B3561E72662FBE6EB77424C6CF9E852;jsessionid=48FD400854722EAA9233B97BBB9A4283;jsessionid=60238739B2F34634A15F586986642293;jsessionid=9066F83F093952A2C700D8AE88761875;jsessionid=2EB981516E01CD98213D68F4C966FA78;jsessionid=F0D58779B34C6465231613701B112E50;jsessionid=D61B914D8FE7178E32486982387D2C57;jsessionid=19B23510BC05FA5090FF014E4C51F090